glp-1 conference food beverage retail fitness speaking opportunities [WEBINAR] How drugs change the game for and beverage, retail, travel and beyond Slideshow: GLP-1 friendly innovations on

Individual variability is significantsome gastroparesis patients tolerate low-dose GLP-1 therapy, while others experience severe adverse effects at any dose

Growing Advocacy : Medical and patient advocacy groups are pushing for obesity to be treated as a chronic condition, not a cosmetic issue, reinforcing the need for long-term, reimbursed care pathways

You can contact us or book an online appointment for both locations

Mental health concerns require appropriate evaluation and support

Among people who took a GLP-1 in the past but stopped, 22% say injections were the main reason they discontinued treatment, and 30% say injections were one of the reasons they stopped

287 The currently developed JHU-083 is a prodrug of 6-Diazo-5-oxo-L-norLeu (L-DON) generation glutaminase inhibitor that selectively activates L-DON in the TME